Loading
Stage Iv Lung Cancer AJCC V8 / Computed Tomography / Metastatic Lung Non Squamous Non Small Cell Carcinoma · Phase 2 Trial
ClinicalTrials.gov · August 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active Phase 2 registration for a three-arm trial testing cabozantinib monotherapy and cabozantinib plus nivolumab versus standard chemotherapy in metastatic or recurrent non-squamous NSCLC. No efficacy or safety results are posted in this registry record; the trial is still recruiting or under analysis. Clinicians and researchers should await final publications before drawing conclusions about comparative effectiveness.
Phase 2, Interventional, Randomized, Parallel, Open label, Treatment purpose. Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8; age from 18 Years. Intervention: Step 1, Arm A (cabozantinib S-malate); Step 1, Arm B (cabozantinib S-malate, nivolumab); Step 2, Arm Z (cabozantinib S-malate, nivolumab). Compared with: Step 1, Arm C (standard chemotherapy) — Active Comparator. n = 117. 611 sites: United States.
This is an active Phase 2 registration for a three-arm trial testing cabozantinib monotherapy and cabozantinib plus nivolumab versus standard chemotherapy in metastatic or recurrent non-squamous NSCLC. No efficacy or safety results are posted in this registry record; the trial is still recruiting or under analysis. Clinicians and researchers should await final publications before drawing conclusions about comparative effectiveness.
No efficacy or safety results are reported in this registry record; trial status is active but not yet recruiting. Effect sizes, confidence intervals, p-values, and any interim safety signals are not available.
The source did not state who this applies to in practice.
This is an active Phase 2 trial registration with no results posted; the study design and rationale are described but no efficacy or safety outcomes are reported.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04310007). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 117 participants (ESTIMATED). Conditions: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8. Interventions: PROCEDURE: Biospecimen Collection; DRUG: Cabozantinib S-malate; PROCEDURE: Computed Tomography; DRUG: Docetaxel; PROCEDURE: Echocardiography Test; DRUG: Gemcitabine Hydrochloride; DRUG: Nab-paclitaxel; BIOLOGICAL: Nivolumab; DRUG: Paclitaxel; BIOLOGICAL: Ramucirumab. Primary outcome measures: Progression-free survival (PFS) for patient population with non-squamous no-small cell lung cancer (NSCLC) , After 58 events (From time of randomization to documented disease progression [site review of imaging] or death from any cause, whichever occurs first). Brief summary: This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as docetaxel, gemcitabine hydrochloride, paclitaxel, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cabozantinib alone or in combination with nivolumab may be more effective than standard chemotherapy in treating patients with non-small cell lung cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.